CRISPR Therapeutics AG - Company Profile

All the sales intelligence you need on CRISPR Therapeutics AG in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how CRISPR Therapeutics AG fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with CRISPR Therapeutics AG.

Back to companies

CRISPR Therapeutics AG: Segment Analysis

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Related keylists

Top 10 Emerging Pharmaceutical Companies in Europe in 2021 by Revenues

Business Description

CRISPR Therapeutics AG (CRISPR Therapeutics) is a biotechnology company focused on developing transformative gene-based medicines for serious human diseases. The company specialises in CRISPR-based therapeutics, utilising CRISPR/Cas9 technology for gene editing. Its primary activities include the development of therapies for genetic diseases and engineering advanced cellular therapies. CRISPR Therapeutics operates in the biotechnology industry, serving sectors such as hemoglobinopathies, oncology, autoimmune diseases, cardiovascular diseases, and diabetes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

CRISPR Therapeutics has undertaken several R&D initiatives, focusing on the development of gene editing technologies, including CRISPR/Cas9, to create transformative gene-based medicines for serious human diseases. The company has launched an early-stage research team called CRISPR-X, which is working on next-generation gene editing modalities, such as whole gene correction and insertion without requiring homology-directed repair or viral delivery of DNA. The company is also involved in collaborative efforts with Vertex Pharmaceuticals to develop and commercialise gene-edited therapies for hemoglobinopathies and diabetes. The R&D units of CRISPR Therapeutics AG include its principal offices in Zug, Switzerland, and its U.S. Additional research and development activities are based in San Francisco, California, and the company has a cell therapy manufacturing facility in Framingham, Massachusetts. These units are responsible for managing the company's R&D activities, including product discovery, preclinical and clinical development, and manufacturing processes. The company has multiple R&D centers, including those in Zug, Boston, San Francisco, and Framingham. The company has entered into major technology alliances, such as its collaboration with Vertex Pharmaceuticals. In FY2024, the company’s R&D expenses stood at US$320.7 million, which declined 17.1% YoY.

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Who We Are

Industries We Cover

Who We Serve

Corporates

Financial Institutions

Professional Services

Other

What We Offer

Intelligence Centers

Consultancy

Marketplace